Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RB1 | P06400 | 7/20 | 0.65 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CDC42 | P60953 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320201 | 0.84 | RB1 (0.70) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL13748402 | 0.80 | RB1 (0.68) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL4144167 | 0.79 | CYP2D6 (0.73) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL25293118 | 0.78 | RB1 (0.62) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL25248626 | 0.78 | RB1 (0.62) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL4196304 | 0.78 | RB1 (0.62) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL13733492 | 0.78 | BRD3 (0.61) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL4196380 | 0.78 | RB1 (1.00) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4160613 | 0.77 | RB1 (0.63) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4162233 | 0.77 | RB1 (1.00) | RB1BRD3SIRT1SIRT2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | RB1 4460/4885BRD3 4059/4885SIRT1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.